Trial Profile
The NK-1 antagonist, Fosaprepitant, versus Ondansetron for prevention of postoperative nausea and vomiting
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Aug 2015
Price :
$35
*
At a glance
- Drugs Fosaprepitant (Primary) ; Ondansetron
- Indications Postoperative nausea and vomiting
- Focus Therapeutic Use
- 03 Aug 2015 Status changed from recruiting to completed, as reported by University Hospital Medical Information Network - Japan.
- 22 Jan 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
- 07 Sep 2013 Planned number of patients changed from 60 to 200 as reported by University Hospital Medical Information Network - Japan.